A recent study conducted by Dr. med. Michael Winkelmann and his colleagues at the LMU Klinikum München explored the association between TGR dynamics from pre-treatment to post-treatment imaging and the patients' outcomes.
 The research provides valuable insights into the potential of TGR as a novel prognostic imaging biomarker in the context of CAR-T therapy for patients with relapsed or refractory non-Hodgkin's lymphoma.

Study with mint Lesion™ Uncovers the Impact of Tumor Growth Rate in Predicting the Efficacy of CAR-T-cell Therapy in Lymphoma Patients
Related Resources
Related Resources

Study Discovers Overdiagnosis of Progressive Cancer in Routine Clinical Evaluations
A recent retrospective study led by Dr. Marilyn J. Siegel and her team at the Washington University School of Medicine in St. Louis has shed light on…

University Hospital Jena: Research Investigating the Viability of Accelerating Whole-Body MRI in Children and Adolescents through STIR DWI with Simultaneous Multi-Slice Excitation
This study[1] addressed the challenges of conducting WB-MRI in paediatric patients, particularly the prolonged acquisition time required for…

WUSTL: Discrepant Assessments of Progressive Disease in Clinical Trials between Routine Clinical Reads and Formal RECIST 1.1 Interpretations
In this retrospective study utilizing the mint Lesion™ software[1], researchers found that routine clinical interpretations frequently resulted in the…